A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Rani Therapeutics Holdings, Inc.
RANI
$24M
Mkt Cap
$0.85
-4.39%
Rani Therapeutics Holdings, Inc. (RANI) has a 5-year average return on invested capital (ROIC) of -84.8%. This is below average and may indicate limited pricing power.
Rani Therapeutics Holdings, Inc. (RANI) has a market capitalization of $83M. It is classified as a small-cap stock.
Rani Therapeutics Holdings, Inc. (RANI) does not currently pay a regular dividend.
Rani Therapeutics Holdings, Inc. (RANI) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Rani Therapeutics Holdings, Inc. (RANI) generated $-36 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Rani Therapeutics Holdings, Inc. (RANI) has a debt-to-equity ratio of 12.36. This indicates higher leverage, which may increase financial risk.
Rani Therapeutics Holdings, Inc. (RANI) reported earnings per share (EPS) of $-1.05 in its most recent fiscal year.
We are a clinical stage biotherapeutics company focusing on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. We are advancing a portfolio of oral therapeutics using our proprietary delivery technology and we are actively pursuing partnering the technology with third party biopharmaceutical companies for the oral delivery of their biologics and drugs. Our technology comprises a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. We have two configurations of the platform – the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. We have completed three Phase 1 clinical trials using the RaniPill GO.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0 | - | 0 | 0 | - |
| Net Income | -28M | -30M | -34M | -31M | -8.3M |
| EPS | $-0.77 | $-1.05 | $-1.33 | $-1.28 | $-0.43 |
| Free Cash Flow | -28M | -36M | -52M | -48M | -33M |
| ROIC | -2305.2% | -184.4% | -91.0% | -46.3% | -17.6% |
| Gross Margin | - | - | - | - | - |
| Debt/Equity | 0.00 | 12.36 | 2.28 | 0.79 | 0.00 |
| Dividends/Share | $0.00 | - | - | - | - |
| Operating Income | -45M | -53M | -66M | -63M | -52M |
| Operating Margin | 0.0% | - | - | - | - |
| ROE | 0.0% | -404.1% | -264.0% | -72.6% | -17.6% |
| Shares Outstanding | 98M | 29M | 26M | 24M | 19M |
| Metric | |||||
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | N/A | 0 | 0 | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -52M | -63M | -66M | -53M | -45M |
| Op. Margin | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -8.3M | -31M | -34M | -30M | -28M |
| Net Margin | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 3.7M | 3.7M |
| Returns on Capital | |||||
| ROIC | -17.6% | -46.3% | -91.0% | -184.4% | N/M |
| ROE | -17.6% | -72.6% | -264.0% | -404.1% | 0.0% |
| ROA | -6.7% | -26.3% | -58.7% | -63.5% | -279.3% |
| Cash Flow | |||||
| Op. Cash Flow | -32M | -47M | -51M | -35M | -28M |
| Free Cash Flow | -33M | -48M | -52M | -36M | -28M |
| Owner Earnings | -55M | -63M | -71M | -53M | -45M |
| CapEx | 506K | 1.6M | 1.2M | 268K | 0 |
| Maint. CapEx | 497K | 548K | 822K | 1.0M | 1.0M |
| Growth CapEx | 9K | 1.1M | 407K | 0 | 0 |
| D&A | 497K | 548K | 822K | 1.0M | 1.0M |
| CapEx/OCF | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 23M | 16M | 19M | 16M | 16M |
| Debt Repayment | 0 | 0 | 0 | 5.0M | 5.0M |
| Balance Sheet | |||||
| Net Debt | -117M | 2.1M | 24M | 21M | 9.4M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | 4.1M |
| Long-Term Debt | 0 | 29M | 24M | 9.6M | 9.6M |
| Debt/Equity | 0.00 | 0.79 | 2.28 | 12.36 | 0.00 |
| Interest Coverage | -110.7 | -59.2 | -13.0 | -10.6 | -10.6 |
| Equity | 47M | 37M | 13M | 2.0M | -7.9M |
| Total Assets | 124M | 108M | 58M | 37M | 10M |
| Total Liabilities | 77M | 34M | 32M | 33M | 2.1M |
| Intangibles | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -8.3M | -39M | -73M | -103M | -103M |
| Working Capital | 117M | 96M | 43M | 9.9M | 9.9M |
| Current Assets | 120M | 101M | 51M | 30M | 30M |
| Current Liabilities | 2.6M | 4.8M | 8.0M | 20M | 20M |
| Per Share Data | |||||
| EPS | -0.43 | -1.28 | -1.33 | -1.05 | -0.77 |
| Owner EPS | -2.86 | -2.63 | -2.78 | -1.84 | -0.46 |
| Book Value | 2.45 | 1.54 | 0.50 | 0.07 | -0.08 |
| Cash Flow/Share | -1.66 | -1.95 | -2.01 | -1.24 | -0.28 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 19.4M | 23.9M | 25.5M | 28.6M | 97.5M |
| Valuation | |||||
| P/E Ratio | N/A | N/A | N/A | N/A | -1.1 |
| P/FCF | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 7.9 | 3.6 | 6.7 | 20.4 | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -8.8% | -36.6% | -61.3% | -88.1% | -33.5% |
| Market Cap | 373M | 132M | 86M | 41M | 83M |
| Avg. Price | 20.60 | 11.61 | 4.21 | 3.40 | 0.85 |
| Year-End Price | 19.25 | 5.51 | 3.35 | 1.42 | 0.85 |
Rani Therapeutics Holdings, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Rani Therapeutics Holdings, Inc. (RANI) has a return on equity (ROE) of -404.1%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 4 years of financial data for Rani Therapeutics Holdings, Inc. (RANI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Rani Therapeutics Holdings, Inc. (RANI) has a book value per share of $0.07, based on its most recent annual SEC filing.